Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | NQO1 | P15559 | 6/20 | 0.55 |
| ▸ | TOP1 | P11387 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CRHBP | P24387 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | CASP6 | P55212 | 1/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4959579 | 0.91 | ADORA3 (0.60) | ADORA3ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL5107208 | 0.83 | ADORA3 (0.53) | ADORA3ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL4960715 | 0.81 | ADORA3 (0.51) | ADORA3MEN1KMT2APOLBNQO1 | |
| Ethyl Biscoumacetate SCHEMBL42830 | 0.79 | ADORA3 (1.00) | ADORA3ALDH1A1MEN1KMT2ANQO1 | |
| Ethyl Biscoumacetate SCHEMBL29359768 | 0.79 | ADORA3 (1.00) | ADORA3ALDH1A1MEN1KMT2ANQO1 | |
| SCHEMBL4960324 | 0.78 | NQO1 (0.57) | ADORA3MEN1KMT2ANQO1TOP1 | |
| SCHEMBL1647635 | 0.77 | ADORA3 (0.77) | ADORA3ALDH1A1MEN1KMT2ANQO1 | |
| SCHEMBL8144592 | 0.77 | MEN1 (0.71) | MEN1KMT2ANQO1TOP1CYP2C9 | |
| SCHEMBL8443505 | 0.76 | ALDH1A1 (1.00) | ADORA3ALDH1A1KMT2APOLBNQO1 | |
| SCHEMBL4958903 | 0.76 | ADORA3 (0.60) | ADORA3ALDH1A1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2161261-B1 | Materials and methods for treating coagulation disorders | ARMETHEON INC (US) | 2013-08-28 | — | — | EP | disclosed |
| US-7932405-B2 | Halogenated ester derivatives of coumarins for the treatment of coagulation disorders | ARYX THERAPEUTICS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2161261-A1 | Materials and methods for treating coagulation disorders | Aryx Therapeutics (US) | 2010-03-10 | — | — | EP | disclosed |
| US-7666902-B2 | 1,1,1,3,3,3-hexachloro-2-methylpropan-2-yl 4-((4-hydroxy-2-oxo-2H-chromen-3-yl)methyl)benzoate; side effect reduction over warfarin | ARYX THERAPEUTICS, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| EP-1735296-B1 | MATERIALS AND METHODS FOR TREATING COAGULATION DISORDERS | ARYX THERAPEUTICS (US) | 2009-12-09 | — | — | EP | disclosed |
| US-20090082430-A1 | Materials and Methods for Treating Coagulation Disorders | ARYX THERAPEUTICS, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20080027132-A1 | Materials and Methods For Treating Coagulation Disorders | ARYX THERAPEUTICS (US) | 2008-01-31 | — | — | US | disclosed |
| US-7285671-B2 | Materials and methods for treating coagulation disorders | ARYX THERAPEUTICS (US) | 2007-10-23 | — | — | US | disclosed |
| US-20060287388-A1 | Materials and Methods for Treating Coagulation Disorders | ARYX THERAPEUTICS (US) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287388-A1 | Materials and Methods for Treating Coagulation Disorders | F12, F2, SERPINC1 | ADORA3 124/4885ALDH1A1 992/4885MEN1 244/4885 |
| US-20080027132-A1 | Materials and Methods For Treating Coagulation Disorders | F12, F2, SERPINC1 | ADORA3 124/4885ALDH1A1 992/4885MEN1 244/4885 |
| US-20090082430-A1 | Materials and Methods for Treating Coagulation Disorders | F12, F2, SERPINC1 | ADORA3 124/4885ALDH1A1 992/4885MEN1 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.